3-methoxytyrosine and nebicapone

3-methoxytyrosine has been researched along with nebicapone in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hainzl, D; Loureiro, AI; Parada, A; Soares-da-Silva, P; Vieira-Coelho, MA	1
Almeida, L; Falcão, A; Loureiro, A; Machado, R; Maia, J; Silveira, P; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L	1
Almeida, L; Costa, R; Falcão, A; Lopes, C; Loureiro, AI; Machado, R; Nunes, T; Rocha, J; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L	1
Almeida, L; Costa, R; Falcão, A; Fernandes-Lopes, C; Loureiro, AI; Machado, R; Nunes, T; Rocha, JF; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L	1

Trials

3 trial(s) available for 3-methoxytyrosine and nebicapone

Article	Year
Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. European journal of clinical pharmacology, 2003, Volume: 59, Issue:8-9 Topics: Acetophenones; Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Benserazide; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Tyrosine	2003
Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Drugs in R&D, 2008, Volume: 9, Issue:6 Topics: Acetophenones; Adult; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Time Factors; Tyrosine; Young Adult	2008
Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. Clinical therapeutics, 2009, Volume: 31, Issue:10 Topics: Acetophenones; Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Middle Aged; Tyrosine; Young Adult	2009

Other Studies

1 other study(ies) available for 3-methoxytyrosine and nebicapone

Article	Year
BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation. European journal of pharmacology, 2001, May-18, Volume: 420, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Biological Availability; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Methylation; Rats; Rats, Wistar; Time Factors; Tyrosine	2001

Article

Year

BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.

European journal of pharmacology, 2001, May-18, Volume: 420, Issue:1

Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Biological Availability; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Methylation; Rats; Rats, Wistar; Time Factors; Tyrosine

2001